Trained immunity: Target for prophylaxis and therapy

Cell Host & Microbe, Journal Year: 2023, Volume and Issue: 31(11), P. 1776 - 1791

Published: Nov. 1, 2023

Language: Английский

---

Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(2), P. 597 - 597

Published: Feb. 10, 2023

Polyethylene glycol (PEG) is used in Lipid Nanoparticles (LNPs) formulations to confer stealth properties and traditionally anchored membranes by a lipid moiety whose length significantly impacts the LNPs fate vivo. C18 acyl chains are efficiently membrane, while shorter C14 lipids quickly desorbed replaced protein corona responsible for completely different of LNPs. In this context, method predict biological behavior depending on lipid-PEG dissociation was developed using Nanoparticle Tracking Analysis (NTA) serum. Two siRNA-containing were prepared including CSL3 or SM-102 grafted with lipids-PEG (C18, lipids-PEG, Ceramide-PEG). The impact interactions between serum components demonstrated monitoring mean particle size concentration over time. vitro, these low toxicity efficient gene knockdown tumor MDA-MB-231 cells, but found efficiency C18-PEG-based LNPs, it did not C14-PEG-based NTA ability discriminate behaviors according proteins’ interactions. Cer-PEG confirmed have promise LNP formulation.

Language: Английский

---

Rational design and combinatorial chemistry of ionizable lipids for RNA delivery

Journal of Materials Chemistry B, Journal Year: 2023, Volume and Issue: 11(28), P. 6527 - 6539

Published: Jan. 1, 2023

This review will delve into the crucial role of ionizable lipids in development lipid nanoparticles (LNPs) for efficient RNA delivery.

Language: Английский

---

Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group

RMD Open, Journal Year: 2023, Volume and Issue: 9(2), P. e003022 - e003022

Published: June 1, 2023

To better define the spectrum of new-onset post-COVID-19 and vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study.Consecutive cases IRD encountered during 12-month period satisfying one following inclusion criteria: (a) onset manifestations within 4 weeks SARS-CoV-2 infection or (b) administration COVID-19 vaccines ws recruited.The final analysis cohort comprised 267 patients, which 122 (45.2%) in 145 (54.8%) postvaccine cohort. Distribution categories differed between two cohorts: had higher percentage patients classified as having joint (IJD, 52.5% vs 37.2%, p=0.013) while post-vaccine prevalence polymyalgia rheumatica (PMR, 33.1% 21.3%, p=0.032). No differences were detected diagnosed with connective tissue (CTD 19.7% 20.7%, p=0.837) vasculitis (6.6% 9.0%, p=0.467). Despite short follow-up period, IJD PMR patients' response to first-line therapy was favourable, both groups achieving drop baseline disease activity scores ~30% ~70% respectively.Our article reports largest published date vaccines. Although causality cannot be ascertained, possible clinical is broad includes IJD, PMR, CTD vasculitis.

Language: Английский

---

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

Emerging Microbes & Infections, Journal Year: 2024, Volume and Issue: 13(1)

Published: Jan. 23, 2024

Herpes zoster remains an important global health issue and mainly occurs in aged immunocompromised individuals with early exposure history to Varicella Zoster Virus (VZV). Although the licensed vaccine Shingrix has a remarkably high efficacy, undesired reactogenicity increasing demand causing shortage urged development of improved or novel VZV vaccines. In this study, we developed mRNA candidate (named as ZOSAL) containing sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated ionizable lipid nanoparticle. mice rhesus macaques, ZOSAL demonstrated superior immunogenicity safety multiple aspects over Shingrix, especially induction strong T cell immunity. Transcriptomic analysis revealed that both could robustly activate innate immune compartments, Type-I IFN signaling antigen processing/presentation. Multivariate correlation further identified several factors compartments can predict magnitude responses, which increased our understanding mode action two different modalities. Collectively, data superiority subunit vaccine. The platform therefore holds prospects for investigations next-generation development.

Language: Английский

---